A Double-blind, Double Dummy, Randomised, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Flutiform pMDI With Fluticasone pMDI and With Seretide pMDI in Paediatric Subjects Aged 5 to Less Than 12 Years With Moderate to Severe Persistent Reversible Asthma.

Trial Profile

A Double-blind, Double Dummy, Randomised, Parallel Group, Multicentre Study to Compare the Efficacy and Safety of Flutiform pMDI With Fluticasone pMDI and With Seretide pMDI in Paediatric Subjects Aged 5 to Less Than 12 Years With Moderate to Severe Persistent Reversible Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Fluticasone propionate (Primary) ; Formoterol/fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Mundipharma International
  • Most Recent Events

    • 13 Feb 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 22 Oct 2013 Planned end date changed from 1 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 22 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top